drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous, second-generation HER2-targeted CAR T-cell therapy. Patient T cells are engineered with an anti-HER2 scFv linked to CD3ζ plus a co-stimulatory domain (CD28 or 4-1BB) to induce activation, proliferation, cytokine release, and cytotoxicity against HER2-positive tumor cells. Administered by intravenous infusion in a dose-escalation schema; study references possible lymphodepleting preconditioning.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a second‑generation HER2‑specific CAR (anti‑HER2 scFv fused to CD3ζ with a co‑stimulatory domain such as CD28 or 4‑1BB). Upon binding HER2 on tumor cells, the CAR provides activation and co‑stimulation, driving T‑cell proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic lysis of HER2‑positive cancer cells.
drug_name
HER2-E-CART cells
nct_id_drug_ref
NCT05745454